The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Medtronic is capturing demand for its cutting-edge solutions, as recent product launches emerge to drive new growth. With the ...

The platform, which includes the new form factor CGM and the Simplera Sync sensor, is designed for integration with Medtronic ...

Medtronic is experiencing continued adoption of the MiniMed 780G automated insulin delivery system, along with increasing CGM attachment rates and the continued rollout of Simplera Sync.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes.

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in ...

Medtronic (NYSE: MDT ... In diabetes care, the MiniMed 780G insulin pump system uses AI algorithms to predict and adjust insulin delivery based on real-time blood sugar monitoring.